Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide, the active ingredient in Mounjaro, is not measured in millilitres when it comes to dosing — it is measured in milligrams. A 40 ml figure most likely reflects the total liquid volume across a full KwikPen, which contains four once-weekly doses. Understanding the difference between volume and dose matters, because the two numbers describe different things: how much fluid is in the pen versus how much medicine is delivered per injection. Mounjaro is a prescription-only medicine in the UK, and a GPhC-registered prescriber determines which strength is appropriate for each person following a clinical assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most detailed evidence on tirzepatide comes from SURMOUNT-1, a 72-week trial involving 2,539 adults with obesity. Participants at the highest dose saw average body-weight reductions in the region of 20–21%, results that directly informed NICE's appraisal of tirzepatide (TA1026), published in December 2024. Throughout that trial, doses were described entirely in milligrams: 5 mg, 10 mg, and 15 mg maintenance doses, each delivered in a small subcutaneous injection via a pre-filled pen. The volume of fluid injected each week is tiny (fractions of a millilitre per dose) and is not a figure the prescriber or patient tracks. What matters clinically is the milligram strength.
The search term "40 ml tirzepatide" almost certainly originates from the pen's total reservoir volume, or from confusion with compound tirzepatide preparations seen in other markets (notably the United States, where compounded versions in larger vials were produced during a shortage period). In the UK, Mounjaro is licensed and supplied only as the Eli Lilly KwikPen in six fixed strengths. There is no 40 ml vial, no compounded form, and no bulk liquid product approved by the MHRA for use in the UK.
Understanding this distinction protects you. Products sold online described in millilitre volumes, bulk quantities, or at very low prices should prompt caution, the MHRA has warned publicly about counterfeit and illegally traded weight-loss medicines, with large seizures of fake pens over recent years. If a product's description doesn't match the licensed Mounjaro format, that is a reason to walk away and report it via the MHRA Yellow Card scheme.
Each Mounjaro KwikPen is a pre-filled, multi-dose pen containing four once-weekly injections. You attach a new needle for each use, inject subcutaneously into the abdomen, thigh, or upper arm, and rotate sites. The pen is designed so that you do not need to measure fluid or set a dial, the dose is pre-set to the pen's licensed strength. After the fourth dose, the pen is finished and disposed of in a sharps container.
Storage matters for the pen's integrity. Mounjaro should be kept refrigerated between 2°C and 8°C. Many people find keeping it in the fridge door, beside other everyday items, works well as a reminder, the pen doesn't need to be hidden or stored separately. The exact room-temperature window, for when you're travelling or the pen needs to come out ahead of injection, is detailed in the Patient Information Leaflet; always check that rather than relying on a general figure.
The six UK strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) are described in the NHS patient information for tirzepatide. Treatment typically begins at 2.5 mg, a starting strength intended to let the body adjust rather than to deliver the full therapeutic effect, before the prescriber moves through the schedule in roughly four-week steps. The pace and endpoint of titration are clinical decisions, not something a patient determines from the pen's volume.
The MHRA licence covers adults managing their weight alongside a reduced-calorie diet and increased physical activity. The standard threshold is a BMI of 30 or above; a BMI of 27 or above qualifies when at least one weight-related condition is present, for example, high blood pressure, raised cholesterol, type 2 diabetes, or obstructive sleep apnoea. For some ethnic backgrounds, UK guidance applies thresholds 2.5 kg/m² lower. BMI alone does not guarantee a prescription; the prescriber reviews the complete clinical picture.
NICE recommends tirzepatide (TA1026) within the NHS for adults with a BMI of 35 or above plus at least one weight-related comorbidity, with NHS rollout phased by cohort from June 2025. Private treatment sits alongside that, offering access without a referral or a waiting list for people who meet the licensed criteria. You can read more about how tirzepatide works as a treatment and explore the broader context of weight-loss treatment options in the UK.
If you are considering tirzepatide and have questions about what the cost of private treatment involves (and what an all-inclusive price actually covers) the Mounjaro cost context page sets that out honestly. The short version: a legitimate private prescription includes clinical assessment, the medicine from a licensed supply chain, and ongoing prescriber oversight.
If you encountered a product described this way (whether on a social-media ad, a marketplace listing, or an unfamiliar website) it is worth pausing before taking any action. Licensed Mounjaro in the UK does not come in a 40 ml format, and if you want to understand the options that are available, you can find full details on our 1 ml tirzepatide, 10 ml tirzepatide, and 20 ml tirzepatide information pages, which explain what those descriptions mean and why they do not correspond to any MHRA-licensed product. The MHRA's published guidance on GLP-1 medicines is clear that the only safe route to tirzepatide is a prescription issued following a proper clinical assessment, dispensed by a pharmacy you can verify on the GPhC register.
Verifying a pharmacy takes about thirty seconds at the GPhC pharmacy register. If a seller cannot be found there, or if the product's description does not match the licensed pen format, those are significant red flags. Counterfeit injectable medicines have caused serious harm in the UK; the MHRA's guidance and enforcement record on this is not a formality.
For accurate information about the Mounjaro product as licensed in the UK, including how to start a Mounjaro assessment, the process is straightforward: a free consultation reviewed by a GPhC-registered prescriber, ID and weight verified, and treatment dispatched the same day if clinically appropriate. Our clinical team and the full details of our approach are available if you want to understand how a registered online pharmacy operates before you start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.